SCHEMBL190294

SCHEMBL190294

CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)C(CC)N(CCO)CCO

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
DNM1 Q05193 6/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
GBA1 P04062 1/20 0.34
GGPS1 O95749 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1038114 1.00 LMNA (0.42) LMNAALDH1A1HSD17B10MEN1KMT2A
Fluoride SCHEMBL3259338 0.98 LMNA (0.41) LMNAALDH1A1HSD17B10MEN1KMT2A
Fluoride SCHEMBL11097713 0.94 LMNA (0.43) LMNAALDH1A1HSD17B10MEN1KMT2A
Avridine SCHEMBL6741009 0.91 LMNA (0.35) LMNAALDH1A1HSD17B10MEN1KMT2A
Fluoride SCHEMBL11099490 0.90 LMNA (0.46) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL268149 0.88 DNM1 (0.39) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL10994980 0.81 LMNA (0.44) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL1970702 0.81 LMNA (0.44) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL31099214 0.80 LMNA (0.39) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL28833442 0.79 LMNA (0.42) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211842-A1 Methods and Devices for the Treatment of Food Allergies TEXAS TECH UNIVERSITY SYSTEM 2022-07-07 US claimed
US-11369671-B2 Vaccine to prevent mycoplasmal infections in waterfowl GALENBIO, INC. (US) 2022-06-28 US claimed
EP-3688146-A1 PORCINE ASTROVIRUSES AND THE USES THEREOF Ceva Sante Animale (FR) 2020-08-05 EP claimed
EP-3630175-A1 METHODS AND DEVICES FOR THE TREATMENT OF FOOD ALLERGIES Texas Tech University System (US) 2020-04-08 EP claimed
WO-2019057953-A1 PORCINE ASTROVIRUSES AND THE USES THEREOF CEVA SANTE ANIMALE (FR) 2019-03-28 WO claimed
EP-3460053-A1 PORCINE ASTROVIRUSES AND THE USES THEREOF Ceva Sante Animale (FR) 2019-03-27 EP claimed
WO-2018222874-A1 METHODS AND DEVICES FOR THE TREATMENT OF FOOD ALLERGIES TEXAS TECH UNIVERSITY SYSTEM (US) 2018-12-06 WO claimed
EP-3310384-A1 VACCINE COMPOSITION CureVac AG (DE) 2018-04-25 EP claimed
WO-2016203025-A1 VACCINE COMPOSITION CUREVAC AG (DE) 2016-12-22 WO claimed
US-20160082094-A1 VACCINE TO PREVENT MYCOPLASMAL INFECTIONS IN WATERFOWL GALENBIO, INC. 2016-03-24 US claimed
US-20050238662-A1 Circovirus sequences associated with piglet weight loss disease (PWD) AGENCE FRANCAISE DE SECURITE SANITAIRE DES ALIMENTS 2005-10-27 US claimed
US-20050118200-A1 Vaccines for Mycoplasma bovis and methods of use LEONARD JOAN D (US) 2005-06-02 US claimed
US-20040258715-A1 Porcine circoviruses, vaccines and diagnostic reagents MERIAL SAS (FR) 2004-12-23 US claimed
EP-1427349-A2 INTERLEUKIN-12 AS A VETERINARY VACCINE ADJUVANT Wyeth (US) 2004-06-16 EP claimed
US-20040009897-A1 Stabilized synthetic immunogen delivery system VAXXINITY, INC. 2004-01-15 US claimed
US-6660272-B2 For protection against Porcine Multisystemic Wasting Syndrome also called Post- weaning Multisystemic Wasting Syndrome MERIAL (FR) 2003-12-09 US claimed
US-20030129161-A1 Interleukin-12 as a veterinary vaccine adjuvant WYETH 2003-07-10 US claimed
WO-2003024354-A2 INTERLEUKIN-12 AS A VETERINARY VACCINE ADJUVANT WYETH (US) 2003-03-27 WO claimed
WO-2000051647-A2 ANIMAL MODEL OF ALLERGIES MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) 2000-09-08 WO claimed
US-5080896-A Adjuvant Coupled to Antigen AKZO N. V. (NL) 1992-01-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160082094-A1 VACCINE TO PREVENT MYCOPLASMAL INFECTIONS IN WATERFOWL MYH10, RAD50, S100A10 LMNA 1153/4885ALDH1A1 4300/4885HSD17B10 760/4885
US-20040009897-A1 Stabilized synthetic immunogen delivery system TLR9, MYD88, IFNG LMNA 3884/4885ALDH1A1 4884/4885HSD17B10 4816/4885
US-11369671-B2 Vaccine to prevent mycoplasmal infections in waterfowl MYH10, RAD50, S100A10 LMNA 1153/4885ALDH1A1 4300/4885HSD17B10 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.